Literature DB >> 8971163

Deletion map of chromosome 16q in ductal carcinoma in situ of the breast: refining a putative tumor suppressor gene region.

T Chen1, A Sahin, C M Aldaz.   

Abstract

Allelic losses or imbalances affecting chromosome arm 16q appear to be early genomic abnormalities in breast carcinogenesis, because they were observed in a significant number of breast ductal carcinoma in situ lesions in our previous study (Aldaz et al., Cancer Res., 55: 3976-3981, 1995). To define the minimum region of loss of heterozygosity (LOH), we generated a high-resolution allelotype of 35 ductal carcinoma in situ cases and completed a deletion map of chromosome 16q by means of paraffin-embedded tissue microdissection and PCR microsatellite analysis of 22 markers. We observed a strikingly high frequency of LOH in 16q, with 31 of 35 tumors (89%) affected. We identified three distinctive areas with high LOH. Two areas were described previously and correspond to 16q21 and 16q24.2-qter. The third and most commonly affected area spanned the region from marker D16S515 to marker D16S504. The most affected locus was at D16S518, in which LOH was observed in 20 of 26 informative cases (77%), and we estimate that it lies in subregion q23.3-q24.1. The region of highest LOH spanned approximately 2-3 Mb, as determined by a yeast artificial chromosome contig reported to cover this region. Such a high frequency of LOH at a preinvasive stage of breast cancer suggests that a candidate tumor suppressor gene or genes at this location may play an important role in breast carcinogenesis.

Entities:  

Mesh:

Year:  1996        PMID: 8971163

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

1.  Multiplex genotype analysis of invasive carcinoma and accompanying proliferative lesions microdissected from breast tissue.

Authors:  X Cui; H Feiner; Z Lin; H Li
Journal:  J Mol Diagn       Date:  2000-02       Impact factor: 5.568

Review 2.  Phosphorylation/de-phosphorylation in specific sites of tumor suppressor WWOX and control of distinct biological events.

Authors:  Shenq-Shyang Huang; Nan-Shan Chang
Journal:  Exp Biol Med (Maywood)       Date:  2018-01-08

Review 3.  Common fragile genes and digestive tract cancers.

Authors:  Tamotsu Kuroki; Yoshitsugu Tajima; Jyunichiro Furui; Takashi Kanematsu
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

4.  Loss of heterozygosity on chromosome 16q suggests malignancy in core needle biopsy specimens of intraductal papillary breast lesions.

Authors:  Miwa Yoshida; Hitoshi Tsuda; Sohei Yamamoto; Takayuki Kinoshita; Sadako Akashi-Tanaka; Takashi Hojo; Takashi Fukutomi
Journal:  Virchows Arch       Date:  2012-04-04       Impact factor: 4.064

Review 5.  Alteration of WWOX in human cancer: a clinical view.

Authors:  Izabela Baryła; Ewa Styczeń-Binkowska; Andrzej K Bednarek
Journal:  Exp Biol Med (Maywood)       Date:  2015-02-13

6.  Role of DNA secondary structures in fragile site breakage along human chromosome 10.

Authors:  Laura W Dillon; Levi C T Pierce; Maggie C Y Ng; Yuh-Hwa Wang
Journal:  Hum Mol Genet       Date:  2013-01-07       Impact factor: 6.150

7.  Multiplex loss of heterozygosity analysis by using single or very few cells.

Authors:  Xiangfeng Cui; Helen Feiner; Honghua Li
Journal:  J Mol Diagn       Date:  2002-08       Impact factor: 5.568

Review 8.  WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies.

Authors:  C Marcelo Aldaz; Brent W Ferguson; Martin C Abba
Journal:  Biochim Biophys Acta       Date:  2014-06-14

9.  Genetically abnormal clones in histologically normal breast tissue.

Authors:  P S Larson; A de las Morenas; L A Cupples; K Huang; C L Rosenberg
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

10.  Molecular analysis of WWOX expression correlation with proliferation and apoptosis in glioblastoma multiforme.

Authors:  Katarzyna Kosla; Elzbieta Pluciennik; Agata Kurzyk; Dorota Jesionek-Kupnicka; Radzislaw Kordek; Piotr Potemski; Andrzej K Bednarek
Journal:  J Neurooncol       Date:  2010-06-10       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.